Research programme: anticancer therapeutics - NantCancerStemCell

Drug Profile

Research programme: anticancer therapeutics - NantCancerStemCell

Alternative Names: Small molecule therapies - NantCancerStemCell

Latest Information Update: 23 Jul 2015

Price : $50

At a glance

  • Class Small molecules; Stem cell therapies
  • Mechanism of Action Hypoxia-inducible factor-1 alpha inhibitors; Proto oncogene protein c-myc inhibitors; Tumour suppressor protein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Cancer

Most Recent Events

  • 09 Jul 2015 Sorrento and NantBioScience form a joint venture to develop small molecule therapeutics in USA for Cancer
  • 09 Jul 2015 Early research in Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top